CoChat

BRAFV600E Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts

Open access
Kemper, Kristel, Krijgsman, Oscar, Kong, Xiangjun, Cornelissen-Steijger, Paulien, Shahrabi, Aida, Weeber, Fleur, van der Velden, Daphne L., Bleijerveld, Onno B., Kuilman, Thomas, Kluin, Roel J.C., Sun, Chong, Voest, Emile E., Ju, Young Seok, Schumacher, Ton N.M., Altelaar, A.F. Maarten, McDermott, Ultan, Adams, David J., Blank, Christian U., Haanen, John B., Peeper, Daniel S. · 2016 · Cell Reports
Cited by 82

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

The therapeutic landscape of melanoma is improving rapidly. Targeted inhibitors show promising results, but drug resistance often limits durable clinical responses. There is a need for in vivo systems that allow for mechanistic drug resistance studies and (combinatorial) treatment optimization. Therefore, we established a large collection of patient-derived xenografts (PDXs), derived from BRAF(V600E), NRAS(Q61), or BRAF(WT)/NRAS(WT) melanoma metastases prior to treatment with BRAF inhibitor and after resistance had occurred. Taking advantage of PDXs as a limitless source, we screened tumor lysates for resistance mechanisms. We identified a BRAF(V600E) protein harboring a kinase domain duplication (BRAF(V600E/DK)) in ∼10% of the cases, both in PDXs and in an independent patient cohort. While BRAF(V600E/DK) depletion restored sensitivity to BRAF inhibition, a pan-RAF dimerization inhibitor effectively eliminated BRAF(V600E/DK)-expressing cells. These results illustrate the utility of this PDX platform and warrant clinical validation of BRAF dimerization inhibitors for this group of melanoma patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.celrep.2016.05.064

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 82

Metadata

Authors
Kemper, K., Krijgsman, O., Kong, X., Cornelissen-Steijger, P., Shahrabi, A., Weeber, F., van der Velden, D. L., Bleijerveld, O. B., Kuilman, T., Kluin, R. J. C., Sun, C., Voest, E. E., Ju, Y. S., Schumacher, T. N. M., Altelaar, A. F. M., McDermott, U., Adams, D. J., Blank, C. U., Haanen, J. B., & Peeper, D. S.
Venue
Cell Reports
Publisher
Elsevier BV
Published
2016-06
Volume
16
Issue
1
Pages
263-277
ISSN
2211-1247 (ISSN-L)
OpenAlex
W2424133004
Cited by
82
References
12
FWCI
4.97
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: BRAFV600E Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts. https://app.cochat.ai/papers/10.1016/j.celrep.2016.05.064
The paper
Kemper, K., Krijgsman, O., Kong, X., Cornelissen-Steijger, P., Shahrabi, A., Weeber, F., van der Velden, D. L., Bleijerveld, O. B., Kuilman, T., Kluin, R. J. C., Sun, C., Voest, E. E., Ju, Y. S., Schumacher, T. N. M., Altelaar, A. F. M., McDermott, U., Adams, D. J., Blank, C. U., Haanen, J. B., & Peeper, D. S. (2016). BRAFV600E Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts. Cell Reports. https://doi.org/10.1016/j.celrep.2016.05.064

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.